Stock Scorecard
Stock Summary for Cullinan Oncology Inc (CGEM) - $10.95 as of 12/20/2024 3:22:25 PM EST
Total Score
9 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CGEM
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CGEM
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CGEM
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CGEM
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CGEM (28 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 1 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for CGEM
Financial Details for CGEM
Company Overview |
|
|---|---|
| Ticker | CGEM |
| Company Name | Cullinan Oncology Inc |
| Country | USA |
| Description | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | 3/12/2025 |
Stock Price History |
|
| Last Day Price | 10.95 |
| Price 4 Years Ago | 0.00 |
| Last Day Price Updated | 12/20/2024 3:22:25 PM EST |
| Last Day Volume | 862,713 |
| Average Daily Volume | 569,520 |
| 52-Week High | 30.19 |
| 52-Week Low | 9.24 |
| Last Price to 52 Week Low | 18.51% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 125.61 |
| Sector PE | 40.44 |
| 5-Year Average PE | -3.97 |
| Free Cash Flow Ratio | 1.10 |
| Industry Free Cash Flow Ratio | 15.99 |
| Sector Free Cash Flow Ratio | 27.17 |
| Current Ratio Most Recent Quarter | 24.46 |
| Total Cash Per Share | 9.93 |
| Book Value Per Share Most Recent Quarter | 10.80 |
| Price to Book Ratio | 1.02 |
| Industry Price to Book Ratio | 5.62 |
| Sector Price to Book Ratio | 20.63 |
| Price to Sales Ratio Twelve Trailing Months | 26.88 |
| Industry Price to Sales Ratio Twelve Trailing Months | 14.60 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.53 |
| Analyst Buy Ratings | 8 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 58,228,000 |
| Market Capitalization | 637,596,600 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -237.72% |
| Reported EPS 12 Trailing Months | -2.84 |
| Reported EPS Past Year | -2.30 |
| Reported EPS Prior Year | -3.69 |
| Net Income Twelve Trailing Months | -143,539,000 |
| Net Income Past Year | -153,162,000 |
| Net Income Prior Year | 111,214,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -83.75% |
| Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 578,100,000 |
| Total Cash Past Year | 467,067,000 |
| Total Cash Prior Year | 467,292,000 |
| Net Cash Position Most Recent Quarter | 578,100,000 |
| Net Cash Position Past Year | 465,067,000 |
| Long Term Debt Past Year | 2,000,000 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 453,703,000 |
| Total Stockholder Equity Prior Year | 535,029,000 |
| Total Stockholder Equity Most Recent Quarter | 627,862,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -126,808,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.18 |
| Free Cash Flow Past Year | -134,483,000 |
| Free Cash Flow Prior Year | -127,797,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.88 |
| MACD Signal | -0.82 |
| 20-Day Bollinger Lower Band | 11.13 |
| 20-Day Bollinger Middle Band | 15.75 |
| 20-Day Bollinger Upper Band | 20.38 |
| Beta | -0.12 |
| RSI | 29.58 |
| 50-Day SMA | 17.42 |
| 150-Day SMA | 13.37 |
| 200-Day SMA | 16.74 |
System |
|
| Modified | 12/20/2024 8:48:25 PM EST |